Article
Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival
15 Sept 2017
Abstract excerpt
The recent remarkable advances in multiple myeloma (MM) therapy and outcomes have had mixed impact on patients with adverse risk genetics, many of whom continue to have inferior outcomes. This applies particularly to deletion of chromosome 17p13 [del(17p)], found in ≈10% of newly diagnosed MM (ND) and at higher prevalence in advanced disease. 1 , 2 , 3 , 4 , 5 The TP53 gene is located within the minimally deleted...
Topics
Join the communities discussing this publication.